salesforce.com (CRM) Reports In-Line Q4 EPS; Guides Q1 EPS Below Views
Get Alerts CRM Hot Sheet
Revenue Growth %: +10.9%
Financial Fact:
Interest expense: -21.95M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
salesforce.com (NYSE: CRM) reported Q4 EPS of $0.14, in-line with the analyst estimate of $0.14. Revenue for the quarter came rose 26% to $1.44 billion versus the consensus estimate of $1.44 billion.
Deferred revenue on the balance sheet as of January 31, 2015 was $3.32 billion, an increase of 32% year-over-year, and 35% in constant currency. Unbilled deferred revenue, representing business that is contracted but unbilled and off balance sheet, ended the fourth quarter at approximately $5.7 billion, up 27% year-over-year.
"Salesforce delivered yet another year of exceptional growth, with revenue, deferred revenue and operating cash flow all growing more than 30%, while exceeding our expectations in non-GAAP operating margin improvement," said Marc Benioff, Chairman and CEO, Salesforce. "Salesforce reached $5 billion in annual revenue faster than any other enterprise software company and now it's our goal to be the fastest to reach $10 billion."
salesforce.com sees Q116 EPS of $0.13 - $0.14, versus the consensus of $0.15. salesforce.com sees Q116 revenue of $1.485 - $1.505 billion, versus the consensus of $1.50 billion.
salesforce.com sees FY2016 EPS of $0.67 - $0.69, versus the consensus of $0.69. salesforce.com sees FY2016 revenue of $6.475 - $6.52 billion, versus the consensus of $6.50 billion.
For earnings history and earnings-related data on salesforce.com (CRM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Universal Insurance (UVE) Tops Q1 EPS by 10c
- PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot Guidance, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!